Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in December 2015 on request of the sponsor.
On 28 October 2005, orphan designation (EU/3/05/318) was granted by the European Commission to the University of Oxford, United Kingdom, for recombinant modified vaccinia virus Ankara expressing tuberculosis antigen 85A for the prevention of tuberculosis disease in Bacille Calmette-Guérin (BCG)-vaccinated individuals.
The sponsorship was transferred to Emergent Product Development UK Limited, United Kingdom, in February 2009 and subsequently back to the University of Oxford, United Kingdom, in June 2013.
recombinant modified vaccinia virus Ankara expressing tuberculosis antigen 85A
Prevention of tuberculosis disease in Bacille-Calmette-Guerin-vaccinated individuals
|Orphan designation status||
|EU designation number||
|Date of designation||
University of Oxford
Oxford OX1 2JD
Tel. +44 (0)1865 8574417
Fax +44 (0)1865 857471
Documents related to this orphan designation evaluation
EU/3/05/318: Public summary of positive opinion for orphan designation of recombinant modified vaccinia virus Ankara expressing tuberculosis antigen 85A for the prevention of tuberculosis disease in Bacille-Calmette-Guà©... (PDF/180.66 KB)
First published: 23/09/2009
Last updated: 19/01/2016
EMA/COMP/317369/2005 Rev. 3
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: